1.The challenges of COVID-19 Delta variant: Prevention and vaccine development

He, XM, He, C, Hong,     More...

He, XM, He, C, Hong, WQ, Zhang, K, Wei, XW     Less

MEDCOMM[2688-2663], Published 2021, Volume 2, Issue 4, Pages 846-854

收錄情况： WOS SCOPUS

WOS核心合集引用: 40  2023影響因子:  10.7 

2.SARS-CoV-2 Omicron variant: Immune escape and vaccine development

Ao, DY, Lan, TX, He,     More...

Ao, DY, Lan, TX, He, XM, Liu, J, Chen, L, Baptista-Hon, DT, Zhang, K, Wei, XW     Less

MEDCOMM[2688-2663], Published 2022, Volume 3, Issue 1,

收錄情况： WOS SCOPUS

WOS核心合集引用: 73  2023影響因子:  10.7  发表年影響因子:  9.9 

3.Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant

Zhou, ZC, Du, P, Li,     More...

Zhou, ZC, Du, P, Li, N, Xiong, XX, Tang, SJ, Dai, QN, Wang, TR, Yu, MX, Man, M, Lam, K, Baptista-Hon, DT, Tai, WH, Monteiro, O, Ng, WS, Lee, UM, Liu, ZH, Zhang, K, Li, G     Less

MEDCOMM[2688-2663], Published 2022, Volume 3, Issue 2,

收錄情况： WOS SCOPUS

WOS核心合集引用: 4  2023影響因子:  10.7  发表年影響因子:  9.9 

4.Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single-cell RNA sequencing

Yu, YF, Chen, HZ, Ou     More...

Yu, YF, Chen, HZ, Ouyang, WH, Zeng, J, Huang, H, Mao, LH, Jia, XY, Guan, TH, Wang, ZH, Lin, RC, Huang, ZJ, Yin, HQ, Yao, HR, Zhang, K     Less

MEDCOMM[2688-2663], Published 2024, Volume 5, Issue 3,

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  10.7